Profile data is unavailable for this security.
About the company
Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.
- Revenue in INR (TTM)15.59bn
- Net income in INR3.00bn
- Incorporated1984
- Employees1.57k
- LocationNeuland Laboratories Ltd'A' Block, Ground Floor, 8-2-120/113Rd No 2, Banjara Hills, Sanali Info ParkHYDERABAD 500033IndiaIND
- Phone+91 4 067611600
- Fax+91 4 067611600
- Websitehttps://www.neulandlabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aarti Drugs Ltd | 25.29bn | 1.71bn | 45.20bn | 1.50k | 26.42 | 3.53 | 20.26 | 1.79 | 18.61 | 18.61 | 274.44 | 139.40 | 1.04 | 3.35 | 3.22 | -- | 7.07 | 9.73 | 10.98 | 15.74 | 33.65 | 24.96 | 6.79 | 8.25 | 1.05 | 7.91 | 0.3056 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Shilpa Medicare Ltd | 11.23bn | -6.71m | 49.39bn | 1.03k | -- | -- | 46.45 | 4.40 | -0.0714 | -0.0714 | 131.44 | -- | -- | -- | -- | 10,873,050.00 | -- | 3.89 | -- | 4.92 | 64.42 | 60.22 | -0.0538 | 9.29 | -- | 1.16 | -- | 10.65 | -8.33 | 5.82 | -153.54 | -- | 14.58 | -- |
| Aarti Pharmalabs Ltd | 18.53bn | 2.17bn | 55.01bn | 1.40k | 25.36 | 3.13 | 18.96 | 2.97 | 23.94 | 23.94 | 204.45 | 193.89 | 0.7698 | 1.64 | 3.86 | -- | 9.01 | -- | 12.30 | -- | 44.90 | -- | 11.71 | -- | 1.01 | 18.17 | 0.1397 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Orchid Pharma Ltd | 8.12bn | 1.25bn | 55.64bn | 838.00 | 38.50 | -- | 35.01 | 6.85 | 28.50 | 26.84 | 175.33 | -- | -- | -- | -- | 9,691,729.00 | -- | -1.07 | -- | -1.96 | 41.49 | 45.87 | 15.63 | -3.52 | -- | 4.34 | -- | -- | 19.00 | -0.6456 | 187.87 | -- | 68.72 | -- |
| Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 65.65bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
| Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 69.12bn | 407.00 | -- | -- | -- | 64.79 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
| Marksans Pharma Ltd | 21.03bn | 3.17bn | 76.61bn | 1.40k | 23.98 | -- | 19.79 | 3.64 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
| F D C Ltd | 19.16bn | 2.90bn | 77.38bn | 6.37k | 26.96 | -- | 23.54 | 4.04 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
| Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 78.98bn | 1.41k | 36.93 | -- | 32.80 | 6.76 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Neuland Laboratories Ltd. | 15.59bn | 3.00bn | 79.61bn | 1.57k | 26.53 | 6.21 | 22.13 | 5.11 | 233.89 | 233.89 | 1,214.80 | 999.78 | 0.9135 | 2.33 | 4.24 | -- | 17.59 | 9.25 | 23.58 | 12.71 | 52.92 | 47.21 | 19.25 | 11.99 | 1.33 | 28.78 | 0.0692 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Strides Pharma Science Ltd | 39.53bn | -1.52bn | 80.18bn | 2.85k | -- | -- | 135.55 | 2.03 | -16.88 | -10.96 | 436.72 | -- | -- | -- | -- | 13,871,790.00 | -- | -0.9448 | -- | -1.59 | 58.90 | 49.75 | -4.37 | -2.19 | -- | 0.9061 | -- | -- | 20.13 | 5.33 | 51.93 | -- | -25.10 | -5.59 |
| Wockhardt Ltd | 27.76bn | -5.01bn | 84.96bn | 2.74k | -- | -- | -- | 3.06 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
| Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 99.42bn | 777.00 | 21.86 | 4.29 | 19.31 | 5.87 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | 7.86 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 2.59 |
| Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 100.83bn | 1.82k | 21.44 | 4.32 | 19.23 | 4.42 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Granules India Ltd | 45.06bn | 4.05bn | 104.09bn | 3.65k | 25.67 | 3.23 | 16.99 | 2.31 | 16.73 | 16.73 | 186.06 | 133.08 | 0.8645 | 1.65 | 4.66 | -- | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 51.39 | 8.99 | 11.82 | 0.7706 | 6.13 | 0.2896 | 7.84 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Jubilant Pharmova Ltd | 66.22bn | 378.60m | 113.66bn | 1.03k | 296.22 | -- | 19.39 | 1.72 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
Data as of May 24 2024. Currency figures normalised to Neuland Laboratories Ltd's reporting currency: Indian Rupee INR
14.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matthews International Capital Management LLCas of 30 Sep 2023 | 522.35k | 4.07% |
| HSBC Asset Management (India) Pvt Ltd.as of 30 Apr 2024 | 348.32k | 2.72% |
| The Vanguard Group, Inc.as of 09 May 2024 | 221.51k | 1.73% |
| quant Money Managers Ltd.as of 30 Sep 2023 | 192.07k | 1.50% |
| Ocean Dial Asset Management Ltd.as of 30 Sep 2023 | 170.89k | 1.33% |
| Ocean Dial Advisers Pvt Ltd.as of 31 Jan 2024 | 113.99k | 0.89% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 92.83k | 0.72% |
| BlackRock Fund Advisorsas of 09 May 2024 | 81.46k | 0.64% |
| WhiteOak Capital Asset Management Ltd.as of 30 Apr 2024 | 64.60k | 0.50% |
| Bandhan Asset Management Co. Ltd.as of 30 Apr 2024 | 45.10k | 0.35% |
More ▼
Data from 30 Sep 2023 - 15 May 2024Source: FactSet Research Systems Inc.
